Article Text

Original research
Increasing the low-risk threshold for patients with upper gastrointestinal bleeding during the COVID-19 pandemic: a prospective, multicentre feasibility study
Free
  1. Philip Dunne1,
  2. Victoria Livie2,
  3. Aaron McGowan3,
  4. Wilson Siu4,
  5. Sardar Chaudhary5,
  6. Maximillian Groome2,
  7. Perminder Phull4,
  8. Andrew Fraser5,
  9. Allan John Morris6,
  10. Ian D Penman3,
  11. Adrian J Stanley1
  1. 1Department of Gastroenterology, Glasgow Royal Infirmary, Glasgow, UK
  2. 2Department of Gastroenterology, Ninewells Hospital and Medical School, Dundee, UK
  3. 3Centre for Liver and Digestive Disorders, Royal Infirmary of Edinburgh, Edinburgh, UK
  4. 4Department of Gastroenterology, Aberdeen Royal Infirmary, Aberdeen, UK
  5. 5Department of Gastroenterology, Queen Elizabeth University Hospital, Glasgow, UK
  6. 6Scottish Society of Gastroenteology, Edinburgh, UK
  1. Correspondence to Dr Philip Dunne, Department of Gastroenterology, Glasgow Royal Infirmary, Glasgow G4 0SF, UK; philip.dunne3{at}nhs.scot

Abstract

Objective During the COVID-19 pandemic, we extended the low-risk threshold for patients not requiring inpatient endoscopy for upper gastrointestinal bleeding (UGIB) from Glasgow Blatchford Score (GBS) 0–1 to GBS 0–3. We studied the safety and efficacy of this change.

Methods Between 1 April 2020 and 30 June 2020 we prospectively collected data on consecutive unselected patients with UGIB at five large Scottish hospitals. Primary outcomes were length of stay, 30-day mortality and rebleeding. We compared the results with prospective prepandemic descriptive data.

Results 397 patients were included, and 284 index endoscopies were performed. 26.4% of patients had endoscopic intervention at index endoscopy. 30-day all-cause mortality was 13.1% (53/397), and 33.3% (23/69) for pre-existing inpatients. Bleeding-related mortality was 5% (20/397). 30-day rebleeding rate was 6.3% (25/397). 84 patients had GBS 0–3, of whom 19 underwent inpatient endoscopy, 0 had rebleeding and 2 died. Compared with prepandemic data in three centres, there was a fall in mean number of UGIB presentations per week (19 vs 27.8; p=0.004), higher mean GBS (8.3 vs 6.5; p<0.001) with fewer GBS 0–3 presentations (21.5% vs 33.3%; p=0.003) and higher all-cause mortality (12.2% vs 6.8%; p=0.02). Predictors of mortality were cirrhosis, pre-existing inpatient status, age >70 and confirmed COVID-19. 14 patients were COVID-19 positive, 5 died but none from UGIB.

Conclusion During the pandemic when services were under severe pressure, extending the low-risk threshold for UGIB inpatient endoscopy to GBS 0–3 appears safe. The higher mortality of patients with UGIB during the pandemic is likely due to presentation of a fewer low-risk patients.

  • gastrointesinal endoscopy
  • gastrointestinal bleeding

Data availability statement

All data relevant to the study are included in the article or uploaded as supplementary information.

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

https://bmj.com/coronavirus/usage

Statistics from Altmetric.com

Significance of this study

What is already known on this topic

  • In light of the COVID-19 pandemic, international specialty groups recommended scaling down endoscopy to true emergencies only.

What this study adds

  • Extending the ‘low-risk’ threshold for non-requirement of inpatient endoscopy after upper gastrointestinal bleeding (UGIB) from Glasgow Blatchford Score (GBS) 0–1 to GBS 0–3 appears relatively safe. Fewer low-risk patients present to hospital during the pandemic.

How might it impact on clinical practice in the foreseeable future

  • Our easily reproducible extended low-risk threshold may prevent the need for an additional 11.1% of inpatient endoscopies for UGIB overall, easing the pressures on endoscopy services during peak periods of the pandemic.

Introduction

At the onset of the COVID-19 pandemic in 2020, together with the aerosol-generating nature of endoscopy and related issues of patient and staff safety, the British Society of Gastroenterology and other international specialty groups recommended scaling down endoscopy to true emergencies only.1 2 In addition, the redeployment of some endoscopy staff to COVID-focused acute services underlined the need to rationalise endoscopy provision.

Patients with suspected upper gastrointestinal bleeding (UGIB) and a Glasgow Blatchford Score (GBS) of 0–1 are recognised to be ‘low-risk’ for mortality or rebleeding and can be discharged, with outpatient endoscopy arranged.3–5 Data from a UK study on UGIB showed that patients with GBS 2–3 have endotherapy or surgical intervention rates of 4.2%–4.4% and 96% survival; however, with a GBS >3, the need for endotherapy rises to 9.4% and survival falls below 90%.6 Expanding the ‘low-risk’ definition for patients requiring inpatient endoscopy from GBS 0–1 to GBS 0–3 seems appropriate during peak periods of the pandemic when services are under significant strain.7 In the UK, this could represent approximately 30% of patients presenting with UGIB.8

We designed a multicentre, prospective feasibility study to assess the safety and efficacy of introducing an extended ‘low-risk’ threshold for non-requirement of inpatient endoscopy after suspected UGIB during the initial peak period of the COVID-19 pandemic.

Materials and methods

Study design

This was a multicentre, prospective feasibility study which took place over a 3-month period; 1 April 2020 to 30 June 2020. Data were collected on consecutive, unselected patients presenting with suspected UGIB at five large Scottish hospitals: Aberdeen Royal Infirmary, Glasgow Royal Infirmary (GRI), Ninewells Hospital Dundee (NW), Queen Elizabeth University Hospital Glasgow (QEUH) and Royal Infirmary of Edinburgh.

Study procedures

Patients presenting with GBS 0–1 were managed as per the previously accepted low-risk pathway described in pre-existing guidelines, that is, discharged (unless admission required for other reasons), and to return for outpatient endoscopy when service provision allows. Patients with GBS 2–3 were included in the updated low-risk pathway and discharged to outpatient endoscopy following discussion with the gastroenterologist on call and were to be placed on a high-priority waiting list at each centre. A timeframe for outpatient endoscopy was not specified due to resource uncertainty at the onset of the pandemic. Exceptions were dependent on clinical assessment and judgement, for example, haemodynamic instability (systolic blood pressure <90 mm Hg), known or suspected cirrhosis, or antithrombotic use. For patients discharged without inpatient endoscopy, the policy in all centres was to prescribe high-dose oral proton pump inhibitors (PPIs) for suspected ulcer bleeding until outpatient endoscopy was performed. Patients were otherwise managed as per UK guidelines for UGIB.9

Data collection and predefined outcomes

All patients with suspected UGIB at the participating hospitals were included in the data collection. Data collected included patient characteristics, referral source, presenting GBS and the associated parameters, COVID-19 status, occurrence and timing of endoscopy as well as the relevant endoscopic findings and therapy. Patients were followed up for 30 days, or until death. At each hospital the data were collected by a lead gastroenterology trainee, and anonymised. Collation of the overall study data occurred at GRI, the lead site.

The predefined clinically relevant patient outcomes observed were as follows: Primary: mortality at 30 days, rebleeding at 30 days and length of hospital admission. Secondary outcomes were: need for blood transfusion, administration of endoscopic therapy and requirement for interventional radiology (IR) or surgery. Data and outcomes from GRI, QEUH and NW were compared with prepandemic, prospective, robust UGIB data, available from the same three centres, recorded during a 12-week UGIB study undertaken in Autumn 2018.

Study observations and statistical analysis

Data were assessed using a complete case analysis. For comparison with the prepandemic cohort, Pearson’s χ2 test and Fisher’s exact test were used to compare proportions and the Mann-Whitney U test was used to compare means. A two-tailed significance level of 5% was used in all comparisons. Multiple logistic regression analysis was undertaken to determine independent predictors of survival in the present study cohort using predetermined patient characteristics, comorbidities, endoscopic factors, rebleeding and COVID-19 infection as variables. Statistical calculations were performed using Prism V.9 (GraphPad).

Results

Three hundred and ninety-seven patients were referred with suspected UGIB during the study period, with the number per centre, patient characteristics and outcomes shown in table 1. Two hundred and eighty-four (71.5%) patients received an inpatient endoscopy, 245 (86.2%) of which were performed within 24 hours of presentation. The mean number of referrals per week was 29 (SD=5.1).

Table 1

Patient characteristics, endoscopic findings and outcomes

Endoscopic diagnosis and relevant interventions

Summaries of endoscopic diagnosis and endotherapy rates are included in table 1. Sixty-two per cent (66/106) of peptic ulcers required endotherapy and all but one of these patients received subsequent high-dose PPI. Eighty-four per cent (21/25) of patients who had oesophageal varices were treated with endoscopic band ligation. Twelve of 288 (4.2%) index endoscopies required subsequent IR or surgery due to refractory or recurrent bleeding, the reasons for which are available in online supplemental data 1.

Mortality, rebleeding and length of stay

Comparisons between low and high-risk groups are shown in table 1. For all patients, 30-day all-cause mortality rate was 13.1% (53/397); for pre-existing inpatients who developed UGIB, the all-cause mortality rate was 33.3% (23/69). Mortality rates were consistent between centres (online supplemental data 2). The 30-day rebleeding rate was 6.3% (25/397) for all patients and 8.7% (9/69) for pre-existing inpatients. For all patients receiving inpatient endoscopy, median length of stay following the procedure was 5 days (IQR 3–8) and median unit of blood transfused was 1 (IQR 0–3, 173 patients).

Low-risk patient group

Of the 84 (21.2%) patients with GBS 0–3, 41 had a GBS of 0–1 and 43 had a GBS of 2–3. Nineteen (22.6%) of these patients underwent inpatient endoscopy due to clinical concern, the reasons for which are outlined in online supplemental data 3. Two (2.4%) patients (both GBS=3) received endotherapy—one had oozing oesophagitis treated with epinephrine spray and the other had gastric varices requiring thrombin injection. Ten outpatient endoscopies were performed by the time of data collection closure (ie, 30 days of follow-up). Of these 10 outpatients, endoscopy was normal in 7, and 3 had grade A-B oesophagitis, with 0 requiring endoscopic therapy. None of the 65 patients who were discharged without inpatient endoscopy were readmitted or died during follow-up.

The overall 30-day all-cause mortality rate in the GBS 0–3 group was 2.4% (2/84). One death was in a pre-existing inpatient (GBS=1) who was deemed unfit for endoscopy due to intercurrent illness (aspiration pneumonia, aged 80) and later died of sepsis. The other death was in a patient with cirrhosis (GBS=3) who presented with one coffee ground vomit. The patient was admitted following clinician concern due to underlying cirrhosis and shortly afterwards had a major haemorrhage. Urgent endoscopy revealed gastric varices requiring endotherapy with thrombin, but the patient subsequently died.

There were no differences in outcomes between patients with GBS 0–1 and GBS 2–3 (table 2). Overall, 10.3% of patients had GBS 0–1 and 21.2% had GBS 0–3.

Table 2

Comparison of outcomes between patients with GBS 0–1 and GBS 2–3 groups

High-risk patients (GBS >3)

Three hundred and thirteen patients had a GBS >3. The mortality rate in this group was 15.3% (48/313) and the rebleeding rate was 7.7% (24/313). Forty-eight (15.3%) of the 313 patients did not receive an endoscopy, 20 (41.6%) of whom died within the 30-day follow-up period. All were considered too unwell to undergo endoscopy. Causes of death in high-risk patients not undergoing endoscopy, as well as reasons for all high-risk patients not undergoing endoscopy, are available in online supplemental data 4.

Patients with COVID-19

Eighty-two patients were deemed to have clinically suspected COVID-19 illness at presentation; however, only 14 of these had a positive PCR test for the SARS-CoV-2 virus recorded. The mortality rate in this group was 20.7% (17/82). Of those who tested positive, five (35.7%) died. Endoscopy was undertaken in five (35.7%) of the patients positive with SARS-CoV-2, none of whom required endotherapy or experienced rebleeding, and all survived beyond 30 days.

Comparison with prepandemic data

When comparing individual results from three centres in the current study with robust consecutive prepandemic data available from the same three centres, there were significantly fewer patients referred with UGIB per week, but a significantly higher mean GBS, and 30-day mortality was observed during the pandemic (table 3). The proportion of patients with GBS 0–3 fell from 33.3% before pandemic to 21.2% during the COVID era (p=0.003). The proportion of patients with GBS 0–1 fell from 13.8% before pandemic to 10.2% during the COVID era (p=0.28).

Table 3

UGIB data during COVID-19 pandemic compared with prepandemic UGIB data at three centres

Multiple logistical regression analysis for mortality

The presence of cirrhosis, being a pre-existing inpatient, age >70 and confirmed SARS-CoV-2 virus were all individual predictors of all-cause mortality (table 4).

Table 4

Multiple regression analysis for 30-day all-cause mortality

Discussion

This multicentre, prospective, feasibility study suggests that extending the threshold for patients with ‘low-risk’ UGIB from GBS 0–1 to GBS 0–3, during peak times of the COVID-19 pandemic, appears to be a relatively safe and pragmatic approach to relieve pressures on endoscopy services. Our data show that the higher mortality of patients with UGIB during the pandemic is associated with a lower proportion of low-risk patients presenting with UGIB. Mortality was predicted by age >70 years, UGIB in pre-existing inpatients, cirrhosis and proven COVID-19 infection.

Eighty-four (21.2%) patients were deemed ‘low-risk’ on the new extended threshold pathway (GBS 0–3). Two (2.4%) of these patients died during the 30-day follow-up, one due to sepsis and one bleeding related. Nineteen underwent inpatient endoscopy, two of whom required endotherapy, one of which was arguably unnecessary. No low-risk patients experienced rebleeding. However, it is imperative to ensure that clinical judgement is also used when felt appropriate. This could include patients presenting with UGIB and GBS 0–3, but who have haemodynamic instability, underlying cirrhosis or those taking antithrombotic medication. This was emphasised by the patient who had a calculated GBS=3 at presentation but was admitted in view of known cirrhosis. This patient had a significant bleed very soon after admission requiring endotherapy for gastric variceal bleeding, but subsequently died. We believe that clinical judgement is an important aspect of any extended low-risk strategy. A clinician’s ‘gut feeling’ has been shown to be an independent predictor of intervention, rebleeding and mortality in patients with UGIB, and is most effective when combined with prediction scores such as the GBS.10

Clinical guidance and pathways during the COVID-19 pandemic required review with consideration of developing COVID-19 minimised, and COVID-19 ‘hot’ services. For the endoscopy service, these pathways help to prioritise patients for emergency endoscopy at times when resources may be reduced due to available staffing and personal protective equipment (PPE).11 Therefore, we believe our easily reproducible pathway, which appears to reduce the requirement for inpatient endoscopy in a relatively safe manner, may be applied in other centres during peak times of the pandemic. This may be relevant for some time, given ongoing waves of infection and the appearance of numerous variants of the virus.

A marked reduction in hospital presentations with non-respiratory illness during the COVID-19 pandemic has been observed.12 In particular, fewer attendances with UGIB have been reported.13 14 A previous study comparing UGIB data to prepandemic UGIB data observed a statistically significant increase in 30-day in-hospital mortality during the pandemic.13 Although the study was not able to demonstrate causation, it was postulated that the mortality increase was due to a secondary effect of the pandemic. We also observed a reduction in the number of patients presenting with UGIB per week during the pandemic compared with prepandemic levels. In addition, we observed an increase in 30-day all-cause mortality during the pandemic, although gastrointestinal bleeding-related mortality was similar. Contrary to the previous study,13 our data show that the mean GBS at time of referral was significantly higher during the pandemic, with a lower proportion of patients presenting with GBS 0–3 compared with prepandemic data. This suggests that patients referred with UGIB during the pandemic were at higher risk of poor outcomes. The higher GBS and mortality rate are probably due to under-representation of lower risk patients, who may have avoided hospital due to the pandemic. Our 30-day mortality rate of 33.3% for pre-existing inpatients is consistent with other studies that show a significantly higher mortality in patients with UGIB who are already in hospital for another reason.15 16

Previous data describe both endoscopic findings and patient outcomes for those infected with the SARS-CoV-2 virus. Eighty-two patients in our study were clinically suspected to have COVID-19; however, only 14 were confirmed to have the SARS-CoV-2 virus on PCR testing. This may have been because PCR testing was not available to all patients at the time of the study, and that we know that PCR is not 100% accurate. There were no endoscopic findings unique to those patients with confirmed COVID-19, none rebled and we found that a positive PCR test was independently associated with mortality.

We are the first to implement and report a new threshold for UGIB endoscopy that can be used during times of severe pressure on hospitals during a pandemic. To our knowledge, this is also the largest study to date on UGIB outcomes during the COVID era. In addition, our multicentre design, prospective data collection, consistent practice and predefined clinical outcomes across sites should be considered strengths of the study. We also acknowledge the limitations. These include the fact that the five centres are all large, teaching hospitals, therefore the results may not be applicable to smaller hospitals. We did not include admission to intensive care units (ICU) as a parameter in our data collection sheet, therefore cannot report on this outcome. Access to ICU beds for patients with UGIB may have been restricted due to the pressures from other patients with SARS-CoV-2. In Scotland, there were 1282 hospital admissions with COVID-19 in the first week of our data collection, and only 16 in the final week.17 However, the country remained in ‘full-lockdown’ throughout our study and endoscopy units remained under pressure during this period due to redeployment of staff, PPE use and availability, and increased procedure turnaround time. When comparing our data with prepandemic data, we were only able to directly compare data from three sites from a different time of year (spring vs autumn). However, we are unaware of any robust data showing different UGIB presentation rates and outcomes throughout the year. A small number of planned outpatient endoscopies for low-risk patients had occurred by the end of the data collection period; however, we were able to observe electronic clinical records throughout and know that no such patient re-presented to hospital or died within 30 days.

In conclusion, during periods of severe pressure on endoscopy services from COVID-19, extending the low-risk threshold for inpatient endoscopy in acute UGIB to GBS 0–3 appears to be relatively safe and could be considered in other centres. The higher GBS and increased mortality of patients with UGIB during the pandemic are associated with the presentation of a reduced proportion of lower risk patients.

Data availability statement

All data relevant to the study are included in the article or uploaded as supplementary information.

Ethics statements

Ethics approval

Approval to undertake the study was granted by the Public Benefit and Privacy Panel for Health and Social Care, Scotland (reference 2021-019) in addition to the local data protection officer at each centre.

References

Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Footnotes

  • Twitter @GastronautIan

  • Contributors PD: design of study, data collection and analysis, drafting and critical revision of manuscript. VL, AM, WS, SC: data collection and critical revision of manuscript. AJM: design of study and critical revision of manuscript. MG, IDP, PP, AF: supervision of study and critical revision of manuscript. AJS: design of study, supervision of study, drafting and critical revision of study. AJS is the guarantor of the study.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.